Darwish, Mona
Youakim, James M.
Harlick, Jim
DeKarske, Daryl
Stankovic, Serge
Funding for this research was provided by:
Acadia Pharmaceuticals Inc.
Article History
Accepted: 19 April 2022
First Online: 27 May 2022
Declarations
:
: This study was sponsored by Acadia Pharmaceuticals Inc. Medical writing and editorial support was provided by Lesley Taylor, PhD, and Stuart Murray, MSc, of Evidence Scientific Solutions, Inc. (Philadelphia, PA) and funded by Acadia Pharmaceuticals Inc.
: Acadia Pharmaceuticals Inc. is adhering to current US and EU requirements so will not make individual de-identified participant data available; however, the protocol and statistical analysis plan will be made available upon request to the corresponding author.
: Not applicable.
: All requisite study-related material, including the protocol, were reviewed by an institutional review board/ethics committee (IntegReview, USA). All subjects provided written informed consent for participation in the study. The study was performed in full conformity with the current Declaration of Helsinki, the International Council for Harmonisation Guideline for Good Clinical Practice, and all other applicable regulations.
: DD, JH, JMY, MD, and SS are employees of Acadia Pharmaceuticals Inc.
: All subjects provided written informed consent for participation in the study.
: Not applicable.
: All authors met ICMJE criteria by contributing to the conception, design, analysis, and/or interpretation of data; drafting the work or revising it critically for important intellectual content; approving the final version to be published; and agreeing to be accountable for all aspects of the work by ensuring that questions related to the accuracy or integrity of any part of the work were appropriately investigated and resolved.